Patient and Provider Attitudes towards Monitored Naltrexone Treatment of Alcohol Dependence in Schizophrenia

REFERENCES

• Westermeyer J. Comorbid schizophrenia and substance abuse: a review of epidemiology and course. Am J Addict 2006; 15: 345–355
   PubMed Web of Science ®Google Scholar
• Walsh E, Buchanan A, Fahy T. Violence and schizophrenia: examining the evidence. Br J Psychiatry 2002; 180: 490–495
   PubMed Web of Science ®Google Scholar
• Wallace C, Mullen P E, Burgess P. Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders. Am J Psychiatry 2004; 161(4)716–727
   PubMed Web of Science ®Google Scholar
• Hunt I M, Kapur N, Windfuhr K, Robinson J, Bickley H, Flynn S, Parsons R, Burns J, Shaw J, Appleby L. Suicide in schizophrenia: findings from a national clinical survey. J Psychiatr Pract 2006; 12(3)139–147
   PubMedGoogle Scholar
• Compton M T, Weiss P S, West J C, Kaslow N J. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Soc Psychiatry Psychiatr Epidemiol 2005; 40(12)939–946
   Google Scholar
• Kemmler G, Hummer M, Widschwendter C, Fleischhacker W W. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: A meta-analysis. Archives of General Psychiatry 2005; 62: 1305–1312
   PubMed Web of Science ®Google Scholar
• Coodin S, Staley D, Cortens B, et al. Patient factors associated with missed appointments in persons with schizophrenia. Canadian Journal of Psychiatry 2004; 49: 145–148
   PubMed Web of Science ®Google Scholar
• Valenstein M, Blow F C, Copeland L A, McCarthy J F, Zeber J E, Gillon L, Bingham C R, Stavenger T. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 2004; 30: 255–264
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology 2005; 8: 267–280
   PubMed Web of Science ®Google Scholar
• Petrakis I L, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal J H, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2004; 172: 291–297, [Erratum appears in Psychopharmacology (Berl). 2004; 174(2):300.]
   PubMed Web of Science ®Google Scholar
• Batki S L, Dimmock J A, Wade M, Gately P W, Cornell M, Maisto S A, Carey K B, Ploutz-Snyder R. Monitored naltrexone without counseling for alcohol abuse/dependence in schizophrenia-spectrum disorders. American Journal on Addictions 2007a; 16: 253–259
   PubMed Web of Science ®Google Scholar
• Batki S L, Dimmock J A, Ploutz-Snyder R, Carey K B, Maisto S A, Cavallerano M, Gallinger L, Leontieva L. Naltrexone treatment for patients with schizophrenia and alcohol dependence: The role of adherence—Preliminary findings. Alcoholism Clinical and Experimental Research 2007b; 31(6: suppl.)255A, (abstract S028)
   Google Scholar
• Chick J, Anton R, Checinski K, Croop R, Drummond D C, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan M Y, Peters T, Ritson B. A multicentre, randomized, double-blind, placebo controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcoholism 2000; 35: 587–93
   PubMed Web of Science ®Google Scholar
• Kay S R, Fiszbein A, Opler L A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13: 261–276
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry 1993; 39–44, Supplementum
   Google Scholar
• McLellan A T, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the Addiction Severity Index. Subst Abuse Treat 1992; 9: 199–213
   PubMed Web of Science ®Google Scholar
• Sobell L CSM. Timeline Follow-Back. The Humana Press, Inc., Totowa, NJ 1992
   Google Scholar
• Lussier J P, Heil S H, Mongeon J A, Badger G J, Higgins S T. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006; 101: 192–203
   PubMed Web of Science ®Google Scholar
• Leontieva L, Dimmock J A, Gately P W, Gallinger L, Ploutz-Snyder R, Batki S L. Voucher-based incentives for naltrexone treatment attendance in schizophrenia and alcohol use disorders. Psychiatric Services 2008; 59(3)310–317
   Google Scholar
• Carey K B, Leontieva L, Dimmock J, et al. Adapting motivational interventions for comorbid schizophrenia and alcohol use disorders. Clinical Psychology: Science and Practice 2007; 14(1)39–57
   PubMed Web of Science ®Google Scholar